![Pictured: Sergio Giralt](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/228/image/giralt-sergio_0.jpg?h=10d202d3)
Sergio A. Giralt, MD
Bone Marrow Transplant Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Bone Marrow and/or Stem Cell Transplantation for Blood Disorders
- Treatment of Multiple Myeloma, Leukemias, and Lymphomas
Request an Appointment
About Me
- Deputy Division Head, Division of Hematologic Malignancies
- Melvin Berlin Family Chair in Multiple Myeloma
- Chief Medical Officer, MSK Direct
I am a board-certified hematologist-oncologist, and my clinical activity and research focus on stem cell transplantation for patients with blood disorders. I trained and worked for many years at the University of Texas M.D. Anderson Cancer Center, where I was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, I joined the faculty of Memorial Sloan Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Read more
My research focus has been on improving treatments for older patients who have acute and chronic leukemia. My colleagues and I pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Before this discovery, older patients with these diseases were rarely considered candidates for stem cell transplantation procedures using donor cells because of the toxic effects of high-dose chemotherapy. The development of these less intense and less toxic regimens has allowed us to perform transplants for older patients in a safe and effective manner and has changed the standard of care throughout the world. I plan to continue this research in the context of the pioneering T cell depletion techniques developed at Memorial Sloan Kettering. This new approach has dramatically reduced the risk of graft-versus-host disease, a serious complication of donor stem cell transplantation. Disease recurrence after transplantation remains an important cause of treatment failure, and I am a proponent of post-transplant maintenance therapies using a variety of targeted therapies, which we are continuing to explore at Memorial Sloan Kettering.
I am an expert in the treatment of multiple myeloma, a blood cancer that affects plasma cells (the cells that produce the antibodies that protect us against infections). My research in this area has focused on developing new conditioning regimens for autologous transplant, a treatment approach in which patients receive an infusion of their own stem cells or bone marrow following a course of high-dose chemotherapy, as well as developing strategies that will reduce “symptom burden” and make the treatment so tolerable that it can be done on an outpatient basis. Our goal is to deliver the most effective therapies with minimum symptom burden. I led the Myeloma Intergroup Committee of the Blood and Marrow Clinical Trials Network, which developed the current national study looking at the role of consolidation therapy after autologous stem cell transplant for patients with myeloma.
As a strong believer in collaborative science among large academic centers, I have been involved in many multi-institutional projects and until recently chaired the executive board of the Center for International Blood and Marrow Transplant Research. I am also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.
A bone marrow transplant specialist is a doctor with special training in bone marrow transplants.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Bone Marrow and/or Stem Cell Transplantation for Blood Disorders
- Treatment of Multiple Myeloma, Leukemias, and Lymphomas
Education
- MD, Universidad Central de Venezuela
Residencies
- Internal Medicine - Good Samaritan Hospital
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2016-2020)
Fellowships
- Medical Oncology - MD Anderson Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Giralt sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Giralt
- A Phase 2 Study of Isatuximab to Treat Low Blood Cell Counts in People With Blood Cancer Who Had a Stem Cell Transplant from a Donor
- A Phase II Study of Iberdomide in People with Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
- A Pilot Study Assessing the Effects of CAR T-Cell Therapy in Elderly Patients Treated for Lymphoma
- A Study Assessing a Mobile App to Help People with Traumatic Stress After a Stem Cell Transplant
Read more
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Giralt’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sergio A. Giralt discloses the following relationships and financial interests:
-
Amgen
Professional Services and Activities -
Celgene
Professional Services and Activities -
CSL Behring
Professional Services and Activities -
ExpertConnect
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities -
Incyte
Professional Services and Activities -
Janssen Research & Development, LLC
Professional Services and Activities -
Karyopharm
Professional Services and Activities
-
Kite Pharmaceuticals
Professional Services and Activities -
Novartis
Professional Services and Activities -
Omeros
Professional Services and Activities -
Pfizer, Inc.
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
Sanofi US Services Inc.
Professional Services and Activities -
TRM Oncology
Professional Services and Activities -
Xcenda
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].